Bile acids (BA) are synthesized in the liver and secreted into the intestine. In the lumen, enteric 26 bacteria metabolize them from conjugated, primary forms into more toxic unconjugated, 27 secondary metabolites. Secondary BAs can be injurious to the intestine and may contribute to 28 disease. Both the epidermal growth factor receptor (EGFR) and the nuclear farnesoid X receptor 29 (FXR) are known to interact with BAs. In this study, we examined the effects of BAs on 30 intestinal epithelial cell proliferation and investigated the possible roles for EGFR and FXR in 31 these effects. We report that taurine-conjugated cholic acid (TCA) induced proliferation, while 32 its unconjugated secondary counterpart, deoxycholic acid (DCA), inhibited proliferation. TCA 33 stimulated phosphorylation of Src, EGFR, and ERK 1/2. Pharmacological blockade of any of 34 these pathways or genetic ablation of EGFR abrogated TCA-stimulated proliferation. 
eliminated (34), which suggests that the colon may be more capable of tolerating secondary 93 metabolites than the small intestine. While the percentage of unconjugated bile acids begins to 94 rise in the terminal ileum (54), it is not until the colon where the transition from primary into 95 secondary metabolites typically occurs (28). It stands to reason that changes in the bacterial flora 96 within the intestine, especially the terminal ileum, could dramatically increase the concentration 97 of secondary bile acids that is not tolerated well by the small intestine. In NEC, for example, 98 bacteria leading to increased secondary bile acids within the terminal ileum may be a mechanism 99 through which an altered gut microbiome affects the intestinal epithelium. 100
101
The molecular mechanisms through which BAs interact with the intestine are not well 102 understood. BAs are known to modulate signaling via the epidermal growth factor receptor 103 differentially control cell proliferation via preferential activation of either the EGFR or FXR 116 pathway. We found that taurine-conjugated cholic acid (TCA), a primary bile acid, stimulated 117 cell proliferation, while the secondary bile acid DCA inhibited it. The pathways regulating these 118 two opposing effects do involve differential activation of EGFR versus FXR, with the 119 downstream pathways involved converging on Src kinase. 120
Materials and Methods: 123 124

Chemicals, compounds, and antibodies 125
Bile acids, Z-guggulsterone, and GW4064 were purchased from Sigma (St. Louis, MO). PP2, 126 PD98059, and LY294002 were purchased from EMD Millipore (Billerica, MA). The TACE 127 inhibitor TAPI-1 was purchased from Santa Cruz Biotechnology (Dallas, TX). Dulbecco's 128
Modified Eagle Medium (DMEM) and RPMI 1640 medium were purchased from Corning 129 (Manassas, VA). Opti-MEM was purchased from Life Technologies (Eugene, OR). Rabbit 130 monoclonal anti-phospho-EGFR (Tyr1068), rabbit monoclonal anti-phospho-Src (Tyr416 and 131 1% penicillin-streptomycin and 0.1% insulin-transferrin-selenium (ITS, Corning). Cultures were 146 maintained in incubators at 37° in an atmosphere of 5% CO 2 and 95% air. Adherent cells were 147 passaged biweekly at confluence after trypsinization. In preparation for experiments, cells were 148 placed in FBS-deprived media (0.1% FBS) for 24 hours. 
MCE cells expressing either human wild-type EGFR, a 154
kinase-dead EGFR, or a null vector has been previously described (72 . 255
256
Statistical Analysis 257
All data are expressed as mean +/-standard error of at least three independent experiments. 258
Statistical calculations were performed using ANOVA and Student's unpaired t-test with aBonferroni modification to correct for multiple comparisons (GraphPad Prism 6.05, La Jolla 260 CA). A p value of < 0.05 was considered significant. 261 262
Results: 263
Bile acid metabolites exert a differential effect on intestinal epithelial cell proliferation 264
To determine the effects of BAs on cell proliferation, IEC-6 cells were initially treated with BAs 265 at 200 μM, a concentration within the normal physiologic range for individual bile acids (54). 266
Administration of the unconjugated primary BA cholic acid (CA) resulted in a modest but 267 statistically significant decrease in cell proliferation (12.7 ± 3.6 %; Figure 1A ). Initial treatment 268 with the other unconjugated bile acids was toxic at 200 μM as assessed by visual inspection and 269 confirmed using a modified MTS-based assay (not shown), so doses were lowered until no 270 toxicity was seen. Treatment with unconjugated primary (50μM CDCA) and unconjugated 271 secondary (50μM DCA, 25μM LCA) BA inhibited proliferation more than CA (23.2 ± 4.0%, 272
24.3 ± 3.4% and 21.1 ± 4.1% respectively; Figure 1A ). In contrast, glycine-and taurine-273 conjugated BAs did not kill cells or inhibit cell proliferation at 200 μM, and in fact taurine-274 conjugated cholic acid (TCA) stimulated intestinal cell proliferation (23.5 ± 4.4% above 275 baseline; Figure 1B ). The effects of TCA and DCA on proliferation were confirmed by EdU 276 incorporation assays in IEC-6 cells ( Figure 1C-D) . Similar results were seen in young adult 277 mouse colon (YAMC) epithelial cells and mouse small intestine epithelial cells (MSIE), 278 suggesting these effects are not specific to the IEC-6 cell line ( Figure 1E and F). Because DCA is 279 the bacterial metabolic product of TCA, we narrowed our focus of investigation to these two 280 molecules in the reminder of our studies. 281 TCA, an abundant component of normal bile (64), promoted cell proliferation. DCA, which 284 inhibited cell proliferation (Figure 1 ), is the product of bacterial modification of TCA by 285 deconjugation followed by dehydroxylation (2). To determine if the effects seen in Figure 1 were 286 dose-dependent, IEC-6 cells were treated with varying concentrations of TCA or DCA. TCA-287 induced cell proliferation was maximized at 250 µM, while DCA-induced inhibition of 288 proliferation was maximal at 50 µM (Figure 2A 
Taurine-conjugated cholic acid stimulates Src, EGFR and ERK phosphorylation 300
To assess the role of TCA in the activation of the EGFR/Src/ERK pathway, IEC-6 cells were 301 exposed to TCA, lysed and probed via immunoblot using phospho-specific antibodies. TCA 302 stimulated Src (Tyr416), EGFR (Tyr1068), and ERK (Thr202/Tyr204) phosphorylation in a 303 time-dependent manner, with maximal effect seen at 5, 60, and 30 minutes, respectively (Figure 304 to TCA administration ( Figure 3G ). Taken together, these results suggest that TCA-induces 313
intestinal ERK activation that requires EGFR and Src co-activation. To determine if EGFR and 314
Src are co-localized in this process, immunoprecipitation of Src followed by analysis of total Src 315 and EGFR by immunoblotting was done. However, administration of TCA did not appreciably 316 increase baseline levels of EGFR-Src association ( Figure 3H ), suggesting that driving this 317 complex is not a key part of the mechanism by which these kinases are activated. 318 empty vector (EGFR knock-out), wild-type human EGFR or a kinase-inactive EGFR. TCA 330 treatment of EGFR-/-MCE cells expressing wild-type human EGFR resulted in increased 331 proliferation (29.8 % +/-2.5%), while EGFR-/-MCE cells expressing an empty vector or kinase 332 inactive EGFR did not respond to TCA administration ( Figure 4C ). Since metalloproteinases 333 (MMP) have been implicated in the EGFR/Src interaction (42), we tested their role in this 334 signaling cascade using the TACE inhibitor TAPI-1. Inhibition of MMP did not alter the 335 stimulatory effect of TCA on IEC-6 cell proliferation ( Figure 4D) . 336 337
DCA-induced inhibition of cell proliferation is mediated by the nuclear receptor FXR 338
FXR is a nuclear receptor that interacts with bile acids and regulates bile acid transport and 339 synthesis in both the intestine and liver (21, 48). DCA is a strong FXR agonist, while TCA is 340 thought to have little FXR activity (70). We sought to assess if DCA-induced inhibition of 341 intestinal epithelial cell proliferation is functioning through an FXR-dependent mechanism. 342
Since IEC-6 cells express FXR (13), we blocked FXR in IEC-6 cells either pharmacologically 343 with 10 µM Z-guggulsterone ( Figure 5A ), a previously described FXR antagonist (15), or with 344 FXR-specific siRNA knockdown ( Figure 5B ) prior to treatment with DCA. The anti-proliferative 345 effects of DCA were abolished by blocking FXR activity using both methods. We achieved an 346 88% reduction of FXR protein using siRNA ( Figure 5C ) and 82% reduction in FXR gene 347 expression ( Figure 5D ). 348 349 FXR has recently been shown to inhibit Src phosphorylation and may regulate the EGFR 350 pathway (55). Indeed, cells treated with DCA decreased EGFR phosphorylation at two hours to 351 below baseline levels ( Figure 5E ). Src (Tyr416) and ERK phosphorylation did not change withDCA administration up to two hours ( Figure 5F ). Since DCA treatment did not decrease Src 353 phosphorylation at Tyr416 below baseline, we sought to better understand the interaction 354 between DCA and Src by investigating phosphorylation of Tyr527, the inhibitory Src 355 phosphorylation site (49). We found that DCA treatment stimulated Src Tyr527 phosphorylation, 356 which was maximized at two hours ( Figure 5G ).This suggests that DCA may inhibit the EGFR 357 pathway, possibly through its activation of FXR resulting in Src inactivation. 358
359
In vivo, bile acids are taken up into the cell via both passive and active methods. The apical 360 sodium-dependent bile acid transporter (ASBT) is the best described and has the highest affinity 361 for conjugated metabolites (17). Since FXR is an intracellular receptor, we tested cellular entry 362 of DCA. MDCK cells did not express ASBT, while HT29, MSIE, and IEC-6 cells did express 363
ASBT at some level ( Figure 5H ). However, DCA is much more hydrophobic than TCA and can 364 diffuse through the cell membrane via passive diffusion without the need for a transporter (65). 365
To test this hypothesis in our system, we treated cells with DCA or TCA for 30 minutes and 24 366 hours. Bile acids were extracted from media or cell lysates and measured via HPLC-MS. DCA 367 was detected within IEC-6 cytoplasm after 30 minutes. TCA, in contrast, remained largely in the 368 surrounding media ( Figure 5I ). To further support the model that DCA is gaining entry into the 369 cell and acting via an FXR-dependent mechanism, we measured mRNA levels of Fgf15. Fgf15 is 370 a known transcription product of FXR activation by bile acids (22). We extracted mRNA from 371 IEC-6 cells exposed to TCA and DCA. Fgf15 expression increased at 30 minutes and 2 hours 372 after DCA exposure, while there was no increase in Fgf15 expression in TCA-treated cells
TCA and DCA function through convergent pathways 376
Our data suggests that the Src/EGFR/ERK and FXR pathways regulate intestinal epithelial 377 proliferation. To assess how the FXR pathway interacts with TCA-induced cell proliferation, we 378 determined the effect of pharmacologic agonist and antagonist of FXR on IEC-6 cell 379 proliferation. TCA-induced proliferation was blocked by the FXR agonist GW4064. FXR 380 antagonism with Z-guggulsterone, which can stimulate proliferation (55), or TCA alone 381 increased intestinal cell proliferation ( Figure 6A ). This effect did not seem to be additive, 382 possibly suggesting maximal stimulation. GW4064 blocked TCA-induced Src phosphorylation 383 ( Figure 6B ). TCA and DCA appear to offset each other's effects on proliferation, resulting in no 384 significant changes from baseline treatment when these two BAs are combined ( Figure 6C) . 385
Cells treated with TCA, DCA, or in combination were probed for Src phosphorylation at Tyr416 386 and the inhibitory site, Tyr527. TCA-induced phosphorylation of Tyr416 was partially blocked 387 by DCA treatment ( Figure 6D ). DCA treatment increased Tyr527 phosphorylation that was not 388 ablated by TCA treatment ( Figure 6E ). Taken together, these data suggest that TCA and DCA 389 function through two competing pathways that converge at the level of Src kinase. 390
391
TCA and DCA have differential proliferative effects in vivo 392
To test whether TCA and DCA affect enterocyte proliferation in vivo, newborn rat pups were 393
given BA in the context of a well-established neonatal intestinal injury model (35, 52) . Pups 394 were gavage-fed formula three times daily with or without 5mM TCA or DCA and subjected to 395 hypoxia. On day of life four, rodents were sacrificed six hours after intra-peritoneal EdU 396 injection. The terminal 1 cm of small intestine was harvested and stained for EdU. Animals 397 treated with TCA had a reduced incidence of intestinal injury (Table 1 ) and a greater proportionof EdU positive cells (Figure 7 ). Animals treated with DCA had reduced labeling and appeared 399 sicker at the time of sacrifice. DCA levels in the intestine are increased in this model and oral 400 gavage of DCA alone without formula-feeding leads to similar intestinal injury (26). This, along 401 with a short experimental time course, may explain why DCA administration with formula-402 feeding did not increase the incidence of intestinal injury but decreased EdU labeling. 403
Discussion 406
Bile acid metabolites all have similar chemical structure due to their common parent molecule, 408 yet they have vastly different physiologic properties (17, 21, 31, 36) . In this manuscript, we show 409 that the conjugated, primary bile acid TCA is mitogenic to the intestinal epithelium. In contrast, 410 DCA, formed by bacterial metabolism of TCA in the gut, inhibits intestinal cell proliferation. 411
This appears to be due to TCA and DCA acting on distinct, competing pathways that converge 412 on Src kinase. TCA promoted enterocyte proliferation via the activation of Src kinase, EGFR and 413
ERK. While ERK is downstream, it appears that upstream Src and EGFR are both independently 414
required for proliferation and may transactivate one another. The anti-proliferative effect seen 415
with DCA administration appears to involve FXR activation, which results in Src 416 phosphorylation at its inhibitory site (Tyr527). Activation of Tyr527 may be the mechanism 417 through which DCA inhibits EGFR activation. This proposed mechanism is summarized in 418 Figure 8 and describes how bile acid metabolites may have differential effects on the intestinal 419
epithelium. 420 421
It is interesting that TCA, but not other conjugated bile acids, stimulated cell proliferation as 422 early as 24 hours. TCA has been shown to stimulate liver cell proliferation in a cancer model 423 (47). In the intestine, cell proliferation is stimulated by TDCA (68) or GCDCA (38), although 424 this required as many as six days to see these effects. Here, we show that only taurine-conjugated 425 cholic acid stimulates intestinal epithelial cell proliferation in 24 hours using both an increase in 426 cell number and EdU incorporation. It is not known how TCA specifically activates Src or 427 EGFR, whether through direct binding or another mechanism. One possible mechanism is viaanother cell surface receptor, such as TGR5, which is also known to be involved in bile acid 429 signaling (58). This pathway presents an avenue for future study. Bile acids have also been implicated in the activation of the EGFR-Src complex (3, 60, 62, 74) . 470
However, the exact mechanism by which bile acids modulate the complex interaction between 471 these two molecules has yet to be elucidated. Src activation by bile acids has been reported as 472 being upstream of EGFR (51) is negated by adequate levels of TCA. While this may be beneficial in cancer models, 499 proliferation is desirable for injury repair. Furthermore, FXR may be overactive when levels of 500 DCA increase in the terminal ileum (26, 27) where typically there is minimal DCA present. In 501 disease such as NEC where DCA levels are increased (25, 26), activation of FXR by DCA could 502 contribute to intestinal injury. The specific genes transcribed by FXR to control cell proliferation 503 are unknown and beyond the scope of this manuscript. Further understanding of this pathway is 504 crucial, however, to develop therapeutic strategies targeting this receptor. 505
506
While the proliferative effects shown in vitro are modest, they are statistically significant, similar 507 in magnitude to those seen in other settings (12, 23, 32, 67) , and likely biologically significant. 508
Our in vivo model of intestinal injury provides further evidence that bile acids can alter intestinal 509 cell proliferation (Figure 7 ). During times of injury, even modest changes in cell proliferation 510 can be the difference between gut barrier integrity and failure. 511
We have shown the opposing effects on intestinal cell proliferation of two distinct bile acid 512 metabolites: taurine-conjugated cholic acid and its product of bacterial modification, the 513 secondary bile acid deoxycholic acid. Understanding the pathways that control these differential 514 effects will allow us to design therapeutic strategies in diseases where the intestinal bacterial 515 population and bile acid pool are altered. 
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